A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)

This study is testing BRTX-100, a treatment made from the patient's own bone marrow cells (specifically a type of stem cell), injected into a damaged spinal disc to treat chronic low back pain caused by degenerative disc disease. Degenerative disc disease occurs when the cushioning discs between the spinal vertebrae break down over time, causing persistent pain that can be debilitating. Unlike surgery, this minimally invasive injection aims to repair the disc from the inside by using the body's own regenerative cells. Patients must have failed at least 6 months of conservative treatments before enrolling. The study tracks pain reduction and functional improvement over 2 years. You may be eligible if: - You are 18 years or older with chronic low back pain for at least 6 months - You have degenerative disc disease confirmed by MRI - You have failed at least 6 months of conservative treatment (rest, medications, physical therapy, injections) - Your pain is between 40-80mm on a visual analog scale - Your disability score (ODI) is between 30-89 out of 100 You may NOT be eligible if: - You have had prior lumbar spine surgery (discectomy, fusion, laminectomy, etc.) - You have a bleeding disorder or cannot stop blood thinners for the procedure - Your BMI is 40 or above - You are pregnant or of childbearing potential without highly effective contraception - You have HIV, hepatitis C, or a known autoimmune disease affecting the musculoskeletal system Talk to your doctor to see if this trial is right for you.